| 1 |
33341937 | Hypoglycemia and Glycemic Control With Glyburide in Women With Gestational Diabetes and Genetic Variants of Cytochrome P450 2C9 and/or OATP1B3. | 2021 Jul |
7 |
| 2 |
32606720 | The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy. | 2020 |
1 |
| 3 |
31086662 | Frequency of CYP2C9 (*2, *3 and IVS8-109A>T) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin. | 2019 May |
1 |
| 4 |
29802808 | CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide. | 2018 Dec |
3 |
| 5 |
30584236 | OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide. | 2018 Dec 24 |
7 |
| 6 |
28522373 | Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. | 2017 Nov 15 |
1 |
| 7 |
27008632 | Combined Influence of Genetic Variants and Gene-gene Interaction on Sulfonylurea Efficacy in Type 2 Diabetic Patients. | 2016 Mar |
1 |
| 8 |
27561267 | Evaluation of the pharmacokinetics of glibenclamide tablet given, off label, orally to children suffering from neonatal syndromic hyperglycemia. | 2016 Nov |
1 |
| 9 |
24839071 | Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. | 2014 Jul |
1 |
| 10 |
23845193 | Severe hypoglycemia due to possible interaction between glibenclamide and sorafenib in a patient with hepatocellular carcinoma. | 2013 Apr |
2 |
| 11 |
22853867 | Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. | 2012 Oct |
2 |
| 12 |
21084763 | Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. | 2011 |
1 |
| 13 |
21336994 | Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. | 2011 Aug |
8 |
| 14 |
20437462 | Contributions of human cytochrome P450 enzymes to glyburide metabolism. | 2010 May |
1 |
| 15 |
20698928 | Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. | 2010 Oct |
5 |
| 16 |
19515014 | Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. | 2009 |
1 |
| 17 |
18503607 | Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. | 2008 Jul |
1 |
| 18 |
17963417 | Pharmacogenetics of glucose-lowering drug treatment: a systematic review. | 2007 |
1 |
| 19 |
16198656 | CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. | 2005 Oct |
4 |
| 20 |
16342679 | [Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. | 2005 Sep |
6 |
| 21 |
16372821 | Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. | 2005 |
2 |
| 22 |
12920163 | Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes. | 2003 Sep |
4 |
| 23 |
11956508 | In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. | 2002 Apr |
1 |
| 24 |
11956512 | Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. | 2002 Apr |
8 |
| 25 |
12235454 | Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. | 2002 Sep |
6 |
| 26 |
11368292 | Clinical pharmacokinetics of fluvastatin. | 2001 |
2 |
| 27 |
11406737 | Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. | 2001 Jun |
1 |
| 28 |
11602509 | Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. | 2001 Nov |
2 |